White House launches direct to consumer drug site

President Donald Trump on Thursday announced the launch of TrumpRx — a direct-to-consumer website that is key to his administration’s efforts to lower prescription drug costs in the U.S. 

The president said millions of Americans would save money through the platform. But it’s still unclear if all patients — particularly those with insurance coverage — will see more cost savings from using that site to buy their medicines than they would through existing methods. TrumpRx targets people who are willing to pay with cash and forgo insurance, which suggests that patients without or with limited coverage may benefit the most. 

“You’re going to save a fortune and this is also so good for overall health care,” Trump said at an event Thursday night unveiling the website.

The site does not sell drugs directly to American patients, but acts as a central hub that points them to drugmakers that are offering discounts on certain products on their own direct-to-consumer sites, or gives them discount coupons to take to pharmacies. For example, Eli Lilly and Novo Nordisk were already offering their blockbuster obesity drugs at hefty discounts to cash-paying patients, even before the reductions Trump touted on Thursday.

Clicking on the platform’s offer for Lilly’s popular Zepbound weight loss injection sends consumers to the company’s LillyDirect platform, where they can order the treatment and submit prescription details.

In recent months, Lilly, Novo and at least 14 other drugmakers have negotiated agreements with the Trump administration to participate on the platform and voluntarily sell certain medicines at a discount to Medicaid patients. Those landmark deals are part of Trump’s broader “most favored nation” policy, which pushes to link U.S. drug prices to the lowest ones abroad.

At launch, the site features only medications from the first five companies to strike pricing deals with the administration: AstraZeneca, Lilly, EMD Serono, Novo Nordisk and Pfizer, according to a White House fact sheet. It will list drugs from other companies “in the coming months,” the administration said.

The platform is the government’s latest effort to try to rein in U.S. prescription drug prices, which are two to three times higher on average than those in other developed nations — and up to 10 times more than in certain countries, according to the Rand Corp., a public policy think tank.

But TrumpRx “doesn’t seem like it is the only solution” to that issue for most Americans, said Juliette Cubanski, deputy director of the program on Medicare Policy at KFF, a health policy research organization. The cash-pay offerings could be better deals for patients without insurance, but it’s difficult to assess exactly how many people stand to benefit from TrumpRx,…